The solid organ transplant recipient with SARS-CoV-2 infection

Curr Opin Organ Transplant. 2021 Aug 1;26(4):412-418. doi: 10.1097/MOT.0000000000000888.

Abstract

Purpose of review: The COVID-19 pandemic is a major challenge to global health, particularly among vulnerable populations. Here, we describe the emerging epidemiology and relevant data on treatment options for COVID-19. We discuss the implications of current knowledge for solid organ transplant (SOT) recipients.

Recent findings: Risk factors and outcomes of COVID-19 among SOT recipients remain uncertain, but recent data suggest similar outcomes to the general population. Case reports of donor-derived SARS-CoV-2 infection are emerging. Few studies on treatment of COVID-19 among SOT recipients are available, and therefore, general recommendations are similar to the general population. Vaccine efficacy in the SOT population is uncertain.

Summary: COVID-19 remains a significant threat to SOT recipients and studies on treatment and prevention specific to this population are urgently needed. Although vaccines represent the greatest hope to control this pandemic, their efficacy in this immunocompromised population is uncertain.

Publication types

  • Research Support, N.I.H., Extramural

MeSH terms

  • COVID-19 / epidemiology*
  • COVID-19 / prevention & control
  • COVID-19 / therapy
  • COVID-19 Vaccines / administration & dosage
  • Humans
  • Immunocompromised Host
  • Organ Transplantation / statistics & numerical data*
  • Risk Factors
  • SARS-CoV-2*
  • Tissue Donors
  • Transplant Recipients / statistics & numerical data*

Substances

  • COVID-19 Vaccines